WebJul 13, 2024 · VANCOUVER, Washington, July 13, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman as President effective July 9, 2024. Dr. WebJan 26, 2024 · CytoDyn CFO and interim president Antonio Migliarese. (CytoDyn Photo) Nader Pourhassan has been ousted as CEO and president by the board of directors of embattled Vancouver, Wash.-based CytoDyn ...
Courtesy of MGK_2: CytoDyn - CYDY CytoDyn Inc #6560591
WebOct 28, 2024 · Nader Pourhassan, CytoDyn's president and CEO, said he's confident that the company will achieve enough votes for its slate of directors and the 200 million additional shares it wants to issue.... WebApr 13, 2024 · CYDY CytoDyn Inc: Courtesy of MGK_2: CytoDyn Webcast 4/11/2024 2:51 Cyrus Arman: Thank you Christina and Thank y - #6560591 ... And so this includes the recent addition of Jane Conlon Werner as our new Executive Director of Quality. I think we are incredibly fortunate to have been able to recruit Jane to join us here at CytoDyn. ... ford escape bluetooth trouble
CytoDyn Appoints Michael A. Klump to Board of Directors
WebApr 10, 2024 · Kelly previously resigned from his role as a director of the Company on October 13, 2024; this director vacancy was filled on October 13, 2024 with the appointment of Stephen M. Simes to the Board ... WebAug 26, 2024 · Mike Leonard. The legal fight for control of CytoDyn Inc. spread to a second forum, when investors backing a dissident slate of board nominees—whom the drugmaker sued three weeks ago in federal court in Delaware—filed suit in state court against the company and its current directors. The lawsuit was filed Wednesday in Delaware … WebJan 28, 2024 · Settlement includes rescinded shares, board structure changes. Current and former CytoDyn Inc. board members and executives reached a proposed settlement Thursday of a lawsuit in Delaware Chancery Court claiming they enriched themselves at the expense of public investors through “unjustified and oversized awards” of stock and options. elmhurst hospital history